Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Study of AK156 in Primary Osteoporosis Patients
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 600
- Registration Number
- NCT01522521
FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)
- First Posted Date
- 2011-08-31
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Antonio Lazzari
- Target Recruit Count
- 70
- Registration Number
- NCT01426555
- Locations
- 🇺🇸
Boston VAMC, Boston, Massachusetts, United States
🇺🇸Spaulding Rehab. Hospital, Charlestown, Massachusetts, United States
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
- Conditions
- Estrogen Receptor-positive Breast CancerInvasive Ductal Breast CarcinomaStage IB Breast CancerStage IIB Breast CancerProgesterone Receptor-positive Breast CancerStage IIA Breast CancerStage IA Breast Cancer
- Interventions
- Other: laboratory biomarker analysisProcedure: therapeutic conventional surgery
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT01409811
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 4
- Registration Number
- NCT01404702
- Locations
- 🇺🇸
University of Alabama at Birmingham-Children's of Alabama, Birmingham, Alabama, United States
Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers
- Conditions
- Locally Advanced Breast CancerDuctal Histologic TypeWithout Her 2 Overexpression
- Interventions
- Drug: Neoadjuvant therapy
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 53
- Registration Number
- NCT01367288
- Locations
- 🇫🇷
Hopital Femme Mère Enfant, Service de Gynécologie, BRON Cedex, France
Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Wuerzburg University Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT01348269
- Locations
- 🇩🇪
Orthopedic Center for Musculoskeletal Research, Orthopedic Department, University of Wuerzburg, Wuerzburg, Bavaria, Germany
🇩🇪Department of trauma, hand, reconstructive and plastic, University of Wuerzburg, Wuerzburg, Bavaria, Germany
Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect
- Conditions
- Metastatic Breast Cancer With Bone Involvement
- Interventions
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 21
- Registration Number
- NCT01344967
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
- Conditions
- CancerMultiple MyelomaBone MetastasesOncologyHematologic MalignanciesMultiple Myeloma Bone Lesions
- Interventions
- Drug: Placebo to DenosumabDrug: Placebo to zoledronic acid
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1718
- Registration Number
- NCT01345019
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2011-04-25
- Target Recruit Count
- 378
- Registration Number
- NCT01341262
The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion
- Conditions
- Image Changes of Lumbar FusionBone Turnover MarkersBone Mineral Density
- Interventions
- First Posted Date
- 2011-03-08
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT01310465
- Locations
- 🇨🇳
Zhongshan hospital of Fudan university, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.